Basel, 10 February 2016
Chugai's ALK Inhibitor "Alecensa" Trial Stopped Early for Benefit
Demonstrates Statistically Significant Improvement in PFS in a Japanese Phase III Head to Head Study with Crizotinib
Please find attached a press release by Chugai.
Do not hesitate to contact us for any further questions.